| |
Particulars |
3 Months ended
31/12/09 |
3 Months ended 31/12/08 |
9 Months ended
31/12/09 |
9 Monthsended
31/12/08 |
Financial Year
ended 31/03/09 |
| |
|
Unaudited |
Unaudited |
Unaudited |
Unaudited |
Audited |
| 1 |
(a) Net Sale/ Income from Operations |
1180.39 |
336.41 |
2435.15 |
1247.76 |
2,181.84 |
| |
(b) Other Operating Income |
|
|
|
|
0 |
| 2 |
Expenditure |
|
|
|
|
|
| |
Increase/ Decrease in Stock in trade and WIP |
18.23 |
-19.79 |
5.17 |
-5.06 |
-29.14 |
| |
Consumption of RM |
62 |
95.46 |
175.59 |
185.21 |
650.22 |
| |
Purchase of traded goods |
1029 |
238.18 |
2041.44 |
994.74 |
1347.69 |
| |
Employee Cost |
4.98 |
3.78 |
12.18 |
11.67 |
14.83 |
| |
Depreciation |
8.25 |
7.85 |
24.75 |
23.55 |
31.39 |
| |
Other Expenditure |
9.69 |
6.97 |
24.47 |
21.64 |
26.09 |
| |
Total |
1132.15 |
332.45 |
2283.6 |
1231.75 |
2041.08 |
| 3 |
Profit from operations before other income, interest and exceptional items |
48.24 |
3.96 |
151.55 |
16.01 |
140.76 |
| 4 |
Other Income |
2.24 |
2.09 |
6.81 |
6.34 |
8.59 |
| 5 |
Profit before interest and exceptional items |
50.48 |
6.05 |
158.36 |
22.35 |
149.35 |
| 6 |
Interest |
|
0 |
0 |
0 |
0 |
| 7 |
Profit after interest but before exceptional items |
50.48 |
6.05 |
158.36 |
22.35 |
149.35 |
| 8 |
Exceptional items |
0 |
0 |
0 |
0 |
0 |
| 9 |
Profit (+)/ Loss (-) from ordinary activities before tax |
50.48 |
6.05 |
158.36 |
22.35 |
149.35 |
| 10 |
Tax Expense |
0 |
0 |
0 |
0 |
51.83 |
| 11 |
Net Profit (+)/ Loss (-) from Ordinary Activities after tax |
50.48 |
6.05 |
158.36 |
22.35 |
97.52 |
| 12 |
Extraordinary Item (net of tax expenses |
0 |
0 |
0 |
0 |
0 |
| 13 |
Net Profit (+)/ Loss (-) for the period |
50.48 |
6.05 |
158.36 |
22.35 |
97.52 |
| 14 |
Paid-up Equity Share Capital (Face Value of the Share shall be indicated) |
2207.43 |
2207.43 |
2207.43 |
2207.43 |
2207.43 |
| |
Face Value of Equity Shares |
1 |
1 |
1 |
1 |
1 |
| 15 |
Reserve excluding Revaluation Reserves as per Balance Sheet of previous year |
|
|
|
|
436.73 |
| 16 |
Earning Per Share (EPS) |
|
|
|
|
|
| |
(a) Basic & Diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualised) |
0.02 |
0.003 |
0.07 |
0.01 |
0.04 |
| |
(b) Basic & Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised) |
0.02 |
0.003 |
0.07 |
0.01 |
0.04 |
| 17 |
Public Shareholding |
|
|
|
|
|
| |
- No. of shares |
133507360 |
131507360 |
133507360 |
131507360 |
131507360 |
| |
- Percentage of shareholding |
60.48 |
59.57 |
60.48 |
59.57 |
59.57 |
| 18 |
Promoters and promoter group Shareholding |
|
|
|
|
|
| |
a) Pledged/ Encumbered |
|
|
|
|
|
| |
- Number of shares |
0 |
0 |
0 |
0 |
0 |
| |
- Percentage of shares (as a % of the total shareholding of promoter and promoter group) |
0% |
0% |
0% |
0% |
0% |
| |
- Percentage of shares (as a% of the total share capital of the company) |
0% |
0% |
0% |
0% |
0% |
| |
b) Non-encumbered |
|
|
|
|
|
| |
- Number of Shares |
87235200 |
89235200 |
87235200 |
89235200 |
89235200 |
| |
- Percentage of shares (as a% of the total shareholding of promoter and promoter group) |
100% |
100% |
100% |
100% |
100% |
| |
- Percentage of shares (as a % of the total share capital of the company) |
39.52% |
40.43% |
39.52% |
40.43% |
40.43% |
| |
|
|
|
|
|
|
Quarterly Reporting Segmentwise Revenue, Results and Capital Employed under Clause 41 of the Listing Agreement |
| |
Particulars
|
3 Months ended
31/12/09 |
3 Months ended 31/12/08 |
9 Months ended
31/12/09 |
9 Months ended
31/12/08 |
Financial Year
ended31/03/09
|
| |
|
Unaudited |
Unaudited |
Unaudited |
Unaudited |
Audited |
| |
(Net Sale/ income from each segment) |
|
|
|
|
|
| |
Segment Revenue |
|
|
|
|
|
| |
(a) Sale of Pharma & Chemical Products |
1061.94 |
243.04 |
2095.04 |
1015.04 |
1375.19 |
| |
(b) Income from Operation |
110.24 |
84.72 |
312.21 |
203.85 |
755.49 |
| |
(c) IT Activities |
8.21 |
8.65 |
27.9 |
28.87 |
51.16 |
| |
Total |
1180.39 |
336.41 |
2435.15 |
1247.76 |
2181.84 |
| |
Less : Inter Segment Revenue |
|
0 |
|
0 |
0 |
| |
Net Sales/ Income from operations |
1180.39 |
336.41 |
2435.15 |
1247.76 |
2181.84 |
| |
Segment Results |
|
|
|
|
|
| |
(Profit / Loss before tax and interest from each segment) |
|
|
|
|
|
| |
(a) Sale of Pharma & Chemical Products |
38.82 |
3.87 |
121.71 |
18.03 |
128.88 |
| |
(b) Income from Operation |
13.85 |
3.12 |
43.35 |
7 |
42.98 |
| |
(c) IT Activities |
0.19 |
0.14 |
0.59 |
0.43 |
3.92 |
| |
Less : Inter Segment Income |
0 |
0 |
0 |
0 |
0 |
| |
Less: Unallocable Expenditure |
2.38 |
1.08 |
7.29 |
3.11 |
26.43 |
| |
PBT |
50.48 |
6.05 |
158.36 |
22.35 |
149.35 |
